Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience

Santos, Francisco Sousa; Santos, Rita; Leite, Valeriano

doi:10.1159/000501680

Cited by 7 publications

(6 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chief among them is how such results are converted to a real-life scenario practice. Several groups have begun to describe their experience with treating DTC using MKI and its feasibility in many different countries, continents, and contexts (13)(14)(15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)34,35). Findings of previous colleagues as well as our results are summarized in Table 6.…”

Section: Discussionmentioning

confidence: 77%

“…as well as Locati and cols. also described in each report patients that did not undergo thyroid surgery before starting MKI therapy due to unresectable tumors ( 16 , 22 , 30 ). Those patients would not be eligible for previous MKI trials, however in our experience, two of those three patients had clinical benefit of MKI treatment (one PR and one SD).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience

Treistman¹,

Nobre²,

Tramontin³

et al. 2021

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

Objective: The aim of this study was to describe the real-world experience multikinase inhibitors (MKI) in the treatment advanced differentiated thyroid carcinoma (DTC) refractory to radioactive iodine (RAIR) therapy. Subjects and methods: We reviewed the records of all patients with MKItreated DTC from 2010 to 2018. Progression free survival (PFS), response rates (RR) and adverse events (AE) profiles were assessed. Clinical parameters were compared between groups with different outcomes (disease progression and death) to identify possible prognostic factors and benefit from treatment. Results: Forty-four patients received MKI for progressive RAIR DTC. Median PFS was 24 months (10.2-37.7) and median overall survival (OS) was 31 months. Best overall response was complete response in one patient (4.5%), partial response in nine (20.4%), stable disease in twentytwo (50%), and progressive disease (PD) in twelve (27.3%). Seventy-two point 7 percent patients had clinical benefit and AE were mild in most cases (82.7%). Progressive patients were more likely to have FDG positive target lesion than those who did not progress (p = 0.033) and higher maximum SUV on target lesions (p = 0.042). Presence of lung-only metastasis and lower thyroglobulin (Tg) during treatment was associated with stable disease (p = 0.015 and 0,049, respectively). Patients with shorter survival had larger primary tumor size (p = 0.015) and higher maximum SUV on target lesions (p = 0.023). Conclusion: Our findings demonstrate safety and effectiveness of MKI in patients with advanced RAIR DTC. We were able to identify as possible prognostic markers of better outcomes: absence of FDG uptake on target lesions, lower maximum SUV on PET-CT, presence of lung-only metastasis and lower Tg during treatment.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 99%

Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience

Treistman¹,

Nobre²,

Tramontin³

et al. 2021

Archives of Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…( 14 ) Similar improvements were also found in some retrospective studies. ( 16 - 18 ) In our group of patients with DTC and PDTC treated with sorafenib, most patients had a partial response with a decrease in tumor mass, but unfortunately of limited duration, and none were completely cured.…”

Section: Discussionmentioning

confidence: 81%

“…This is similar to results of clinical trials and retrospective studies. ( 17 , 18 , 22 , 23 ) One patient in our study developed gastrointestinal bleeding during sunitinib therapy, which is a possible side effect of the therapy. Hemorrhage has been reported in the literature with certain agents, and one of the sunitinib trials reported a 14% rate of GI bleeding, including one grade 5 event.…”

Section: Discussionmentioning

confidence: 85%

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience

Pešorda

2020

ACC

View full text Add to dashboard Cite

SUMMARY Although most patients with thyroid cancer have a favorable clinical course, some patients develop a more aggressive type of cancer and exhibit more rapid disease progression with worse prognosis. Those patients usually exhibit mutations of proteins such as tyrosine kinase enzymes that play a significant role in regulation of tumor proliferation and spreading. Development of targeted therapies is based on the inhibition of mutated kinases which are involved in the MAPK signaling pathway. The aim of this study was to present the initial results of clinical experience with kinase inhibitors in patients with metastatic differentiated thyroid cancer (DTC), poorly differentiated thyroid cancer (PDTC), and medullary thyroid cancer (MTC) who exhibited rapid disease progression. A total of 17 adult patients (11 women, mean age 53.3 years) managed for progressive, metastatic disease were included in the study. Twelve patients with DTC and PDTC were previously tested for BRAF mutations, of whom nine that had tumor tissue negative for the BRAF V600E mutation received sorafenib, while three patients with tumors harboring the BRAF V600E mutation were treated with vemurafenib. Patients with MTC were treated with sunitinib, vandetanib, and sorafenib. Two patients with tumors harboring the BRAF mutation treated with vemurafenib showed restoration of radioiodine uptake. Most of patients showed significant improvement in disease status but of limited duration until disease progression. Although there was an improvement in progression-free survival, future research has to achieve a greater and longer-lasting response, probably by utilizing combined targeted therapy.

show abstract

“…A study compared sorafenib or sunitinib in 28 RAI-refractory metastatic DTC patients (26 treated with sorafenib as first-line therapy (eight patients switched successively to sunitinib), and two with sunitinib). The PR rate and mean PFS were 30.7% and 10.8 months, respectively, for sorafenib, and 37.5% and 6 months for sunitinib, as a second-line therapy [ 62 ].…”

Section: Braf In Tcmentioning

confidence: 99%

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer

Ragusa

Ferrari

Elia

et al. 2022

IJMS

View full text Add to dashboard Cite

Thyroid cancer is the most common (~90%) type of endocrine-system tumor, accounting for 70% of the deaths from endocrine cancers. In the last years, the high-throughput genomics has been able to identify pathways/molecular targets involved in survival and tumor progression. Targeted therapy and immunotherapy individually have many limitations. Regarding the first one, although it greatly reduces the size of the cancer, clinical responses are generally transient and often lead to cancer relapse after initial treatment. For the second one, although it induces longer-lasting responses in cancer patients than targeted therapy, its response rate is lower. The individual limitations of these two different types of therapies can be overcome by combining them. Here, we discuss MAPK pathway inhibitors, i.e., BRAF and MEK inhibitors, combined with checkpoint inhibitors targeting PD-1, PD-L1, and CTLA-4. Several mutations make tumors resistant to treatments. Therefore, more studies are needed to investigate the patient’s individual tumor mutation burden in order to overcome the problem of resistance to therapy and to develop new combination therapies.

show abstract

Sorafenib and Sunitinib for the Treatment of Metastatic Thyroid Cancer of Follicular Origin: A 7-Year Single-Centre Experience

Cited by 7 publications

References 20 publications

Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience

Prognostic factors in patients with advanced differentiated thyroid cancer treated with multikinase inhibitors – a single Brazilian center experience

Kinase Inhibitors in the Treatment of Thyroid Cancer: Institutional Experience

Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer

Contact Info

Product

Resources

About